MIAMI, Dec. 20, 2019 — Longeveron LLC, a leading developer of adult stem cell technologies for chronic, aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 1 Alzheimer’s disease trial. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild Alzheimer’s disease (AD). [Read more…]
American Journal of Sports Medicine to publish results of an FDA-approved clinical trial for treating knee pain
Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees
Louisville, Colo. and Chicago, Ill. – January 30, 2020 – GID BIO announced the acceptance by the American Journal of Sports Medicine to publish results next month of an FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis. [Read more…]
First Dosing in Plexoval Exosome Wound Healing Human Study
Highlights
- First human dosing of Plexaris™ has occurred in Exopharm’s PLEXOVAL Study
- PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm’s proprietary LEAP Technology for wound healing
- Other pre-clinical development progress will be reported over coming months
MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]
INTELLiSTEM Announces the Launch of a New Antigen Identification Platform for the Development of Novel CAR T Cells
TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy, announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]
Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs
Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.
BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. [Read more…]
- « Previous Page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- …
- 96
- Next Page »